Gabriel Brooks - 18 Oct 2025 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role
Chief Medical Officer
Signature
/s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks
Issuer symbol
SLDB
Transactions as of
18 Oct 2025
Net transactions value
-$17,254
Form type
4
Filing time
21 Oct 2025, 16:05:11 UTC
Previous filing
18 Aug 2025
Next filing
02 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Brooks Gabriel Chief Medical Officer C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN /s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks 21 Oct 2025 0001997809

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLDB Common Stock Options Exercise +9,750 +36% 36,714 18 Oct 2025 Direct F1, F2
transaction SLDB Common Stock Sale $17,254 -2,895 -7.9% $5.96 33,819 20 Oct 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLDB Restricted Stock Units Options Exercise $0 -9,750 -33% $0.000000 19,500 18 Oct 2025 Common Stock 9,750 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 Includes 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 30, 2025.
F3 This sale was made to cover withholding taxes following the vesting of previously granted RSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.
F4 The RSUs were granted on October 18, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.